SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test
SpeeDx Pty. Ltd. today announced Resistance Plus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mgen.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005544/en/
(Photo: Business Wire)
Current Canadian management guidelines for Mgen direct laboratories to forward positive samples to the National Microbiology Laboratory for resistance testing.1 Now Canadian laboratories can utilize Resistance Plus MG and bring this service inhouse to generate more timely results for doctors and their patients.
"SpeeDx tests are designed to empower clinicians to make informed treatment decisions,” said Colin Denver, SpeeDx CEO. “Bringing Resistance Plus MG to Canada allows even more clinicians to access Resistance Guided Therapy, helping to improve patient cure rates and reduce overall health care costs.”
Resistance to azithromycin, a commonly recommended treatment for Mgen infection, has been rising where empiric treatment or Mgen detection only practices have predominated.2 A groundbreaking paper using Resistance Plus MG as part of a Resistance Guided Therapy protocol reported significant success - improving cure rates from below 60% to over 92%.2 Resistance Plus MG is already in use across Europe, U.K., Australia, and New Zealand, where recent STI management guideline updates recommend assessing the resistance status of Mgen infections in order to guide appropriate treatment.3-5
There is not currently a U.S. Food and Drug Administration (FDA) -cleared commercially available test for the combined detection of M. genitalium and macrolide resistance markers. SpeeDx is finalizing clinical trials across the U.S. in preparation for FDA submission later this year. The FDA also recently granted breakthrough status for the SpeeDx Resistance Plus® GC test, supporting Resistance Guided Therapy for gonorrhea infections.6 Resistance Plus GC provides information on ciprofloxacin susceptibility/resistance, giving doctors and patients the option of using ciprofloxacin instead of ceftriaxone, one of the last remaining antibiotics available for multi-drug resistant gonorrhoea infections.
“Our Resistance Plus tests represent a new way of using diagnostics, providing more information on the infecting organism,” adds Denver. “The availability of this kind of testing has now influenced Mgen treatment guidelines around the world and we are delighted with this new registration for Canada as well as the prospect of offering this and other similar tests in the U.S. market in the near future.”
About M. genitalium (Mgen)
M. genitalium is a STI that can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease. In recent studies, it has been found to have a higher prevalence than gonorrhea.7 Like Neisseria gonorrhoeae, Mgen is also evolving into a so-called STI superbug that is becoming resistant to many antibiotic treatments leading to exceedingly difficult to treat infections and threatening global public health.8 Macrolide antibiotics, specifically azithromycin, are the first-line treatment but resistance to these antibiotics has increased.1,9,10 Due to this growing antibiotic resistance problem, several global STI Management Guidelines on Mgen infections recommend complementing the use of molecular testing to detect M. genitalium with an assay capable of detecting macrolide resistance-associated mutations.2-4
SpeeDx has developed a molecular diagnostics test portfolio for infectious diseases that provides identification of infecting organism and therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com
- Read T R H, et al. CID 2019; 68(4):554-560
- Jensen JS, et al. 2016.PMID: 27505296.
- Miller WC et al. JAMA 2004; 291:2229–2236.
- Unemo M & Jensen JS. Nat Rev Urol. 2017; 14:139-152.
- Getman D et al. J Clin Micro 2016; 54:2278-2283.
- Murray GL et al. Emerg Infect Dis 2017; 23(5):809-812.
Europe, Australia, New Zealand
+61 2 9209 4170
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ethereum (ETH) Now Available on bitFlyer Buy/Sell23.8.2019 05:00:00 CEST | Press release
Cryptocurrency exchange bitFlyer has announced it is adding Ethereum (ETH) to its Buy/Sell trading platform. From today, bitFlyer Buy/Sell users across Europe and the US can send and receive ETH while ensuring they adhere to the same robust regulatory standards as bitFlyer guarantees for Bitcoin (BTC) transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005486/en/ Ethereum (ETH) Now Available on bitFlyer Buy/Sell (Graphic: Business Wire) Andy Bryant, Co-head and COO, bitFlyer Europe, said, “At bitFlyer, we want to offer not just the most popular coins, but the most respected ones too, which makes ETH a logical choice to expand our service offering. Not only has ETH proved itself as a useful altcoin, particularly in relation to smart contracts, it has an incredibly strong community that surrounds it. We’re committed to offering the best customer experience whilst prioritising security and regulatory standards, a
STALICLA Announces Completion of pre-IND Meeting With FDA on STP1 for Subgroup of Patients With Autism Spectrum Disorder (ASD)23.8.2019 00:00:00 CEST | Press release
STALICLA, a Swiss Biotech company, today announced the completion of its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) on the preparation for entry of STP1 into clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005559/en/ STALICLA at the Food and Drug Administration (FDA) to discuss its investigational precision medicine for Autism Spectrum Disorder (Photo: STALICLA) “We are appreciative of FDA´s technical guidance and strong interest in personalized medicine approaches for patients with Autism Spectrum Disorder. STALICLA is committed to rapidly move forward with the submission of its STP1 IND. STP1 holds the potential to become the first precision medicine for a subgroup of patients with ASD, and herald a new age for this field.” - Lynn Durham, CEO and Founder of STALICLA. ASD is a common neurodevelopmental disorder, with high level of heterogeneity, that aff
San Fang Chemical Switches to Rimini Street Support for its Oracle EBS and Oracle Database Software22.8.2019 22:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that San Fang Chemical Co., Ltd., a global manufacturer and distributor of artificial leather products headquartered in Taiwan, has switched to Rimini Street support for its Oracle E-Business Suite application and Oracle Database software. In addition to immediately saving 50% of its annual maintenance costs that they were previously paying the vendor, the company can now maintain its core, robust Oracle system for a minimum of 15 years from the time that they switched to Rimini Street support with no forced upgrades. San Fang Chemical has also been able to liberate its IT resources and divert its substantial cost savings to invest in more forward-looking innovation projects to help pave the way for future growth and competitive advantage. This press release features mu
Gravity Unveils its Future Plans During Gamescom 201922.8.2019 15:46:00 CEST | Press release
Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. (NASDAQ: GRVY) which is a leading global game company, participated in Gamescom which is one of the three largest game fairs in the world, held in Cologne, Germany from August 20th to 24th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005507/en/ Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. (NASDAQ: GRVY) which is a leading global game company, participated in Gamescom which is one of the three largest game fairs in the world, held in Cologne, Germany. At the fair, Gravity announced that it plans to launch ‘Ragnarok M: Eternal Love’ in the European region on September 4th 2019. ‘Ragnarok M: Eternal Love’ will be launched in Russia and Turkey, as well as Europe and it will be serviced in seven languages including English, Portuguese, Spanish, Russian, German, French, and Turkish. (Photo: Business Wire) On August 20th, Gravity held a presentati
RoboSense and Aidrivers Announce a Partnership to Deliver Superior Autonomous Solutions for Industrial Transportation22.8.2019 14:55:00 CEST | Press release
RoboSense, the leading supplier of LiDAR perception system solutions, and Aidrivers, the UK's leading provider of autonomous mobility solutions for industrial applications announced today a partnership in system integration. Aidrivers will integrate RoboSense Smart LiDAR Sensor System into their own Autonomous Driving Systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005468/en/ RoboSense and Aidrivers announce a partnership to deliver superior autonomous solutions for industrial transportation Aidrivers is delivering a fully autonomous natural navigation system that meets industrial safety standards to seaports, particularly for horizontal transportation, aimed for improving operation efficiency and leading the way in industrial autonomous mobility automation. Their solution can work under all harsh weather conditions by achieving true 3D mapping and localization for precision positioning and situation cognisance
Alight to Acquire NGA Human Resources, One of the Largest Multi-Country Payroll and HR Solutions Providers in the World22.8.2019 14:00:00 CEST | Press release
Alight Solutions, a leader in technology-enabled health, wealth and human capital management (HCM) and financial management solutions, today announced it has signed a definitive agreement to acquire NGA Human Resources, a leading provider of digital HR and multi-country payroll services. The proposed transaction is subject to customary closing conditions. With a nearly 50-year history, NGA HR brings innovation, high-quality service, HR and payroll expertise to its more than 250 clients, representing three million employees. As one of the largest multinational payroll providers, NGA HR is enabled to deliver HR & payroll services across more than 188 countries. Underpinning NGA HR’s HR and payroll expertise is its industry leading technology platforms including hrX, which provides companies with a centralized point to access their payroll and HR solutions including analytics; and its euHReka multi-tenant cloud payroll platform, which is localized to support payroll in 51 different countr